News Vaxcyte's pneumococcal jab exceeds expectations Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.
News MSD takes a $400m bite of SciBrunch's KRAS drug MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.
News MSD, Daiichi pull filing for lung cancer candidate I-DXd MSD and Daiichi Sankyo's regulatory efforts for their ADCs for cancer have stuttered again, with a withdrawn filing for lung cancer candidate I-DXd.
News FDA starts speedy review of Imfinzi in bladder cancer AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.
News Wnt drug gives MSD first eye disease win after EyeBio deal MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.
News MSD, Moderna skin cancer vaccine scores historic phase 3 win Strong phase 3 results for Moderna's individualised skin cancer vaccine could pave the way for a leap forward in the field.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.